Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).

BMC Cancer · 2023 · PMC10278289 · PMID 37337155

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

It showed a trend for a risk reduction for death for taxane retreated patients in the FOLFIRI group with a mOS of 7,5 months (95% CI 5.9–12.94) compared to 6,6 months (95% CI 0.47–1.43) for the paclitaxel group [ 30 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.